Table 1. Association between CLDN3 expression and clinicopathologic characteristics of patients with ADC.
| Characteristics | No | Claudin3 (+) | Claudin3(−) | χ2P |
|---|---|---|---|---|
| Age (Years) | 0.319 | |||
| ≤60 | 143 | 74(51.7%) | 69(48.3%) | |
| >60 | 118 | 69(58.5%) | 49(41.5%) | |
| Gender | 0.305 | |||
| Male | 124 | 70(56.5%) | 54(43.5%) | |
| Female | 137 | 73(53.3%) | 64(46.7%) | |
| Smoking history | 0.910 | |||
| Never | 140 | 76(54.3%) | 64(45.7%) | |
| Ever | 121 | 67(55.4%) | 54(44.6%) | |
| Tumor size (cm) | 0.275 | |||
| ≤ 3 | 134 | 68(50.7%) | 66(49.3%) | |
| >3 | 127 | 74(61.2%) | 53(38.8%) | |
| T stage | 0.368 | |||
| T1 | 118 | 59(50%) | 59(50%) | |
| T2 | 88 | 53(60.2%) | 35(39.8%) | |
| T3 | 55 | 31(56.4%) | 24(43.6%) | |
| N stage | 0.144 | |||
| N0 | 140 | 74(52.9%) | 66(47.1%) | |
| N1 | 31 | 23(74.2%) | 8(25.8%) | |
| N2 | 90 | 46(51.1%) | 44(48.9%) | |
| TNM stage | 0.551 | |||
| I(IA, IB) | 121 | 65(53.7%) | 56(46.3%) | |
| II(IIA, IIB) | 52 | 32(61.5%) | 20(38.5%) | |
| IIIA | 88 | 46(52.3%) | 42(47.7%) | |
| Histology | ||||
| Micropapillary predominent | 33 | 19(57.6%) | 14(42.4%) | 0.423 |
| Acinar predominent | 29 | 19(65.5%) | 10(34.5%) | 0.513 |
| Lepidic predominent | 99 | 49(49.5%) | 50(50.5%) | 0.029 |
| Solid predominent | 78 | 44(56.4%) | 34(43.6%) | 0.970 |
| Papillary predominent | 22 | 16(72.7%) | 6(26.3%) | 0.509 |
| Recurrence or Metastasis | 0.008 | |||
| Absent | 146 | 69(47.3%) | 77(52.7%) | |
| Present | 115 | 74(64.3%) | 41(35.7%) |